Article and Video CATEGORIES

Cancer Journey

Search By

Ramy Sedhom, MD, is a Medical Oncology Fellow at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.

He is interested in Supportive and Palliative Care for patients across the cancer continuum - from a clinical, research, and policy perspective. Following his oncology training, he will be pursuing a clinical fellowship in Hospice and Palliative Care.

The Role of Immunotherapy in Metastatic Bladder Cancer
Author
Ramy Sedhom, MD, GRACE Guest Faculty
Image

GRACE is excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD.

For this video, Dr. Ramy Sedhom introduces us to Dr. Matthew Galsky with the Tisch Cancer Institute and Icahn School of Medicine at Mt. Sinai in New York.  In this video, Drs. Sedhom and Galsky discuss the role of immunotherapy in metastatic bladder cancer. 


If you have questions or comments, please feel free to join the conversation at https://cancergrace.org/forums/bladder-cancer.

 

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.